Skip to main content
. 2020 Dec 11;99(50):e23695. doi: 10.1097/MD.0000000000023695

Table 4.

Assessment of P2Y12 responsiveness in patients treated without and with PPIs (multiplicative model).

Multiplicative Model
Criteria in Defining LTPR Crude OR (95% CI) P value Adjusted OR (95% CI) P value
(1) Criteria by inhibition >20%
All PPIs 1.28 (0.74–2.20) .3814 1.15 (0.65–2.04) .6295
Individual PPI
 Lansoprazole 0.98 (0.49–1.94) .9426 0.89 (0.44–1.81) .7406
 Dexlansoprazole 3.20 (1.19–8.62) .0212 2.78 (0.99–7.74) .0503
 Pantoprazole 1.37 (0.48–3.92) .5540 1.26 (0.43–3.64) .6744
 Esomeprazole 1.60 (0.54–4.78) .3980 1.47 (0.49–4.44) .4959
 Rabeprazole 0.36 (0.07–1.83) .2168 0.31 (0.06–1.63) .1655
(2) Criteria by PRU < 235
All PPI 1.43 (0.81–2.52) .2137 1.20 (0.67–2.17) .5427
Individual PPI
 Lansoprazole 1.29 (0.63–2.64) .4841 1.10 (0.53–2.229) .8058
 Dexlansoprazole 2.05 (0.85–4.97) .1119 1.63 (0.65–4.10) .2960
 Pantoprazole 2.05 (0.72–5.86) .1804 1.80 (0.62–5.22) .2822
 Esomeprazole 1.79 (0.61–5.30) .2901 1.53 (0.51–4.61) .4467
 Rabeprazole 0.29 (0.04–2.46) .2583 0.23 (0.03–1.99) .1834
(2) Criteria by PRU < 262
All PPIs 1.42 (0.79–2.56) .2472 1.13 (0.61–2.10) .6901
Individual PPI
 Lansoprazole 1.13 (0.53–2.42) .7512 0.91 (0.41–1.99) .8058
 Dexlansoprazole 2.70 (1.10–6.60) .0297 1.93 (0.76–4.86) .1651
 Pantoprazole 1.62 (0.55–4.80) .3858 1.80 (0.62–5.22) .2822
 Esomeprazole 1.80 (0.59–5.44) .2990 1.45 (0.47–4.50) .5230
 Rabeprazole 0.39 (0.05–3.25) .3808 0.28 (0.03–2.35) .2386

LTPR = low on-treatment platelet reactivity, OR = odds ratio, PPI = proton pump inhibitor. Model adjusted using the covariate of dual antiplatelet use.

Statistical significance (P <.05).

Model was adjusted using covariate of dual antiplatelet use.